36 related articles for article (PubMed ID: 1954636)
1. Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs.
Nagasawa K; Ohnishi N; Yokoyama T
Jpn J Cancer Res; 1997 Aug; 88(8):750-9. PubMed ID: 9330607
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of drug resistance in acute myeloid leukemia.
Zhang J; Gu Y; Chen B
Onco Targets Ther; 2019; 12():1937-1945. PubMed ID: 30881045
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of idarubicin 12 mg/m(2) and 8 mg/m(2) combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients.
Zhou L; Liu X; Liu H; Zhu W; Cai X; Song K; Zheng C; Tang B; Sun Z
Onco Targets Ther; 2016; 9():985-91. PubMed ID: 27013891
[TBL] [Abstract][Full Text] [Related]
4. Induction-related cost of patients with acute myeloid leukaemia in France.
Nerich V; Lioure B; Rave M; Recher C; Pigneux A; Witz B; Escoffre-Barbe M; Moles MP; Jourdan E; Cahn JY; Woronoff-Lemsi MC
Int J Clin Pharm; 2011 Apr; 33(2):191-9. PubMed ID: 21744189
[TBL] [Abstract][Full Text] [Related]
5. Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China.
Huang BT; Wang Y; Du QF; Yang J; Yu J; Zeng QC; Xu N; Zhang JF; Xu LL; Luo XJ; Wei YQ; Liu XL
Int J Hematol; 2011 Apr; 93(4):474-481. PubMed ID: 21387092
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic considerations in treating patients with acute leukaemia.
Jønsson V; Hansen MM; Ljungman P; Kaasa S
Pharmacoeconomics; 1999 Feb; 15(2):167-78. PubMed ID: 10351190
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of cost-effectiveness studies.
Pashko S
Pharmacoeconomics; 1992 Apr; 1(4):300-1. PubMed ID: 10147112
[No Abstract] [Full Text] [Related]
8. Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia.
Whittington R; Goa KL
Pharmacoeconomics; 1993 Oct; 4(4):287-307. PubMed ID: 10146918
[TBL] [Abstract][Full Text] [Related]
9. New agents in the treatment of acute myeloid leukemia.
Wiernik PH
Semin Hematol; 1991 Jul; 28(3 Suppl 4):95-8. PubMed ID: 1780763
[No Abstract] [Full Text] [Related]
10. Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation.
Adige S; Lapidus RG; Carter-Cooper BA; Duffy A; Patzke C; Law JY; Baer MR; Ambulos NP; Zou Y; Bentzen SM; Emadi A
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1105-1112. PubMed ID: 30968179
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia.
Pashko S; Jacobs J; Santorsa J
Clin Ther; 1991; 13(3):353-60. PubMed ID: 1954636
[TBL] [Abstract][Full Text] [Related]
12. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
[TBL] [Abstract][Full Text] [Related]
14. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
15. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]